{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:31:52Z","timestamp":1792812712449,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.omtm.2021.02.014","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T23:51:32Z","timestamp":1614124292000},"page":"76-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec"],"prefix":"10.1016","volume":"21","author":[{"given":"John W.","family":"Day","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Menier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"van Olden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitra","family":"Tauscher-Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2691-0200","authenticated-orcid":false,"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2021.02.014_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.omtm.2021.02.014_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2021.02.014_bib3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.02.014_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2021.02.014_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.02.014_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.omtm.2021.02.014_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.10425","article-title":"Genetic risk assessment in carrier testing for spinal muscular atrophy","volume":"110","author":"Ogino","year":"2002","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.omtm.2021.02.014_bib8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2021.02.014_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2021.02.014_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2021.02.014_bib11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fgene.2019.00868","article-title":"Development and clinical translation of approved gene therapy products for genetic disorders","volume":"10","author":"Shahryari","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.omtm.2021.02.014_bib12","series-title":"Zolgensma (onasemnogene abeparvovec-xioi) prescribing information","year":"2019"},{"key":"10.1016\/j.omtm.2021.02.014_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/humc.2017.109","article-title":"Differential prevalence of antibodies against adeno-associated virus in healthy children and patients with mucopolysaccharidosis III: perspective for AAV-mediated gene therapy","volume":"28","author":"Fu","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtm.2021.02.014_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/gt.2014.103","article-title":"AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy","volume":"22","author":"Thwaite","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2021.02.014_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/infdis\/161.3.487","article-title":"Natural history of pertussis antibody in the infant and effect on vaccine response","volume":"161","author":"Van Savage","year":"1990","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omtm.2021.02.014_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fimmu.2014.00446","article-title":"Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies","volume":"5","author":"Niewiesk","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2021.02.014_bib17","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1016\/S0264-410X(03)00336-0","article-title":"Transfer of antibody via mother\u2019s milk","volume":"21","author":"Van de Perre","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.omtm.2021.02.014_bib18","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.02.014_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","article-title":"Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption","volume":"16","author":"Orlowski","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4 Suppl 1","key":"10.1016\/j.omtm.2021.02.014_bib20","first-page":"185","article-title":"Validation of an anti-AAV9 human IgG screening ELISA","volume":"28","author":"Tijsma","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.02.014_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.21732","article-title":"Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins","volume":"66","author":"Mendell","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2021.02.014_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ana.22251","article-title":"Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D","volume":"68","author":"Mendell","year":"2010","journal-title":"Ann. Neurol."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050121000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:31:19Z","timestamp":1762421479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050121000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":22,"alternative-id":["S2329050121000292"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2021.02.014","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2021.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}